ATE277929T1 - Immunsuppressive wirkungen von pteridinderivaten - Google Patents

Immunsuppressive wirkungen von pteridinderivaten

Info

Publication number
ATE277929T1
ATE277929T1 AT99964663T AT99964663T ATE277929T1 AT E277929 T1 ATE277929 T1 AT E277929T1 AT 99964663 T AT99964663 T AT 99964663T AT 99964663 T AT99964663 T AT 99964663T AT E277929 T1 ATE277929 T1 AT E277929T1
Authority
AT
Austria
Prior art keywords
treatment
pteridine derivatives
immunosupressive
effects
rejections
Prior art date
Application number
AT99964663T
Other languages
English (en)
Inventor
Mark Joseph Albert Waer
Piet Andre Maurits M Herdewijn
Wolfgang Eugen Pfleiderer
Original Assignee
4 Aza Bioscience Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4 Aza Bioscience Nv filed Critical 4 Aza Bioscience Nv
Application granted granted Critical
Publication of ATE277929T1 publication Critical patent/ATE277929T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
AT99964663T 1998-12-28 1999-12-28 Immunsuppressive wirkungen von pteridinderivaten ATE277929T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11398998P 1998-12-28 1998-12-28
PCT/EP1999/010320 WO2000039129A1 (en) 1998-12-28 1999-12-28 Immunosuppressive effects of pteridine derivatives

Publications (1)

Publication Number Publication Date
ATE277929T1 true ATE277929T1 (de) 2004-10-15

Family

ID=22352730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964663T ATE277929T1 (de) 1998-12-28 1999-12-28 Immunsuppressive wirkungen von pteridinderivaten

Country Status (8)

Country Link
EP (1) EP1144412B1 (de)
JP (1) JP2002533464A (de)
AT (1) ATE277929T1 (de)
AU (1) AU770551B2 (de)
CA (1) CA2356380C (de)
DE (1) DE69920757T2 (de)
ES (1) ES2229803T3 (de)
WO (1) WO2000039129A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2413324A (en) * 2004-04-22 2005-10-26 4 Aza Bioscience Nv Pharmaceutically active pteridine derivatives
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0004781D0 (sv) * 2000-12-22 2000-12-22 Active Biotech Ab A screening assay for antagonists of human leukocyte receptors
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
AU2004267885A1 (en) * 2003-08-29 2005-03-10 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
GB2405793A (en) * 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
PL1663244T3 (pl) * 2003-09-12 2008-01-31 4 Aza Ip Nv Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
PT1673092E (pt) * 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
KR101123429B1 (ko) 2003-12-30 2012-06-29 바조팜 게엠베하 4-아미노-7,8-다이하이드로프테리다인, 이를 함유한 약학조성물 및 산화 질소 수준의 증가에 의해 야기되는 질병의치료를 위한 이의 용도
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057645A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7691858B2 (en) 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2012167046A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
MD3097102T2 (ro) 2015-03-04 2018-02-28 Gilead Sciences Inc Compuşi de 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2665275A (en) * 1948-12-22 1954-01-05 Allen & Hanburys Ltd 2, 4-diamino-7, 8-disubstituted pteridines
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
DE3213507A1 (de) * 1982-04-10 1983-10-20 Celamerck Gmbh & Co Kg, 6507 Ingelheim N-pteridinylharnstoffe, ihre herstellung und verwendung
EP0108890B1 (de) * 1982-09-20 1988-12-07 The Wellcome Foundation Limited Pharmazeutisch aktive Pteridinderivate
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
DE3833393A1 (de) * 1988-10-01 1990-04-05 Thomae Gmbh Dr K Verwendung von pteridinen zur verhinderung der primaeren und sekundaeren resistenz bei der chemotherapie und diese verbindungen enthaltende arzneimittel
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
DE69733308D1 (de) * 1996-07-31 2005-06-23 Cmic Co Aktivsauerstoffaufnehmer enthaltende pterinderivate
KR100650962B1 (ko) * 1996-08-30 2007-07-18 다이이치 아스비오파마 가부시키가이샤 질소산화물합성효소(nos)의기능저하에의해유발되는질환의예방또는치료제
DK0956855T3 (da) * 1998-04-24 2003-07-14 Leuven K U Res & Dev Immunhæmmende effekter af 8-substituerede xanthin-derivater
US5992713A (en) * 1998-10-23 1999-11-30 Manabat; Gregorio S. Clothes hanger with slidable side attachments

Also Published As

Publication number Publication date
CA2356380A1 (en) 2000-07-06
DE69920757D1 (de) 2004-11-04
EP1144412B1 (de) 2004-09-29
AU3042900A (en) 2000-07-31
ES2229803T3 (es) 2005-04-16
AU770551B2 (en) 2004-02-26
JP2002533464A (ja) 2002-10-08
WO2000039129A1 (en) 2000-07-06
DE69920757T2 (de) 2005-12-15
EP1144412A1 (de) 2001-10-17
CA2356380C (en) 2008-06-17

Similar Documents

Publication Publication Date Title
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0011130A (pt) Inibidores de metaloproteases
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
IS2750B (is) Leiðarafesting
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
SE9801494D0 (sv) Novel use
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
IT1318667B1 (it) Medicamento antinfiammatorio.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1144412

Country of ref document: EP

REN Ceased due to non-payment of the annual fee